Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - H.C. Wainwright maintained its buy rating and $7.00 price target on I-Mab (NASDAQ:IMAB) stock Tuesday as the company prepares to present Phase 1b data for its cancer drug givastomig at the ESMO GI conference on July 2, 2025. Track I-Mab’s real-time performance and access comprehensive financial analysis with InvestingPro, featuring exclusive insights and valuation metrics.
The abstract for the presentation will be released Wednesday, June 25, 2025, at 6:05 PM EST, providing details on givastomig’s performance when combined with nivolumab and chemotherapy in first-line metastatic gastric cancer patients.
H.C. Wainwright views this upcoming data as crucial for assessing the drug’s ability to deliver improved efficacy without compromising safety, noting that givastomig’s conditional 4-1BB activation mechanism could potentially avoid the hepatotoxicity issues that have limited similar drugs.
The research firm highlighted feedback from key opinion leaders suggesting givastomig could generate responses across a wider CLDN18.2 expression spectrum than competing agents like zolbetuximab, potentially more than doubling the addressable patient population.
I-Mab plans to host an investor webinar on July 8, 2025, which will provide additional information on givastomig’s potential positioning within the Claudin 18.2 treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.